Octreotide (Sandostatin)

General information

Class/mechanism: Long-acting octapeptide that suppresses multiple hormones and has physiologic actions similar to somatostatin. It suppresses LH response to GnRH, reduces splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, pancreatic polypeptide, growth hormone, IGF-I (somatomedin C), glucagon, insulin, and TSH.
Route: SC, IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Diseases for which it is used

• Neuroendocrine tumor
• Pancreatic NET
• Thymoma

Patient drug information

• Octreotide (Sandostatin) patient drug information (Chemocare)
• Octreotide (Sandostatin) patient drug information (UpToDate)

History of changes in FDA indication

• 1988-10-21: Initial approval for treatment of chronic and severe diarrhea and flushing episodes associated with carcinoid tumors and vasoactive intestinal peptide-secreting tumors (VIPomas). (No supporting studies are cited)

History of changes in EMA indication

• 1995-06-23: EURD

Also known as

• Code name: SMS-201-995
• Generic names: octreotide immediate release, octreotide IR, octreotide acetate
• Brand names: Longastatina, Mycapssa, Octrestatin, Octride, Okeron, Proclose, Samilstin, Sandostatin, Sandostatina, Sandostatine